EVT 401

Drug Profile

EVT 401

Alternative Names: EVT401

Latest Information Update: 16 Aug 2016

Price : $50

At a glance

  • Originator Renovis
  • Developer Evotec AG; Zhejiang Conba Pharmaceutical
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 16 Aug 2016 Clinical trials in Inflammation in China (PO)
  • 16 Oct 2014 No development reported - Phase-I for Inflammation (In volunteers) in USA (PO, Suspension)
  • 16 Oct 2014 No development reported - Phase-I for Inflammation (In volunteers) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top